Philip M Arlen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Future Oncol 1:19-22. 2005
  2. ncbi request reprint Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1750, USA
    Am J Ther 14:310-3. 2007
  3. ncbi request reprint Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Crit Rev Immunol 27:451-62. 2007
  4. pmc New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
    Vittore Cereda
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:63-71. 2010
  5. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
  6. pmc Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:3060-9. 2008
  7. pmc Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:663-74. 2010
  8. pmc A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
    William D Figg
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Urol 181:1104-13; discussion 1113. 2009
  9. pmc Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant
    Robert J Lechleider
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 14:5284-91. 2008
  10. pmc Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
    Jeanny B Aragon-Ching
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    BJU Int 103:1636-40. 2009

Collaborators

Detail Information

Publications65

  1. ncbi request reprint Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Future Oncol 1:19-22. 2005
    ..Newer approaches are now looking at combinations of other drugs with docetaxel to further improve the overall survival of patients with metastatic androgen-insensitive metastatic prostate cancer...
  2. ncbi request reprint Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1750, USA
    Am J Ther 14:310-3. 2007
    ..The literature also suggests that low-dose ketoconazole may be an appropriate second- or third-line hormonal agent in AIPC, causing a PSA decline, symptomatic relief, and minimal toxicity...
  3. ncbi request reprint Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Crit Rev Immunol 27:451-62. 2007
    ..In addition, clinical studies combining vaccines with radiation therapy, chemotherapy, and second-line hormone therapy have provided preliminary evidence of prolongation of time to disease progression and antigen cascade postvaccination...
  4. pmc New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
    Vittore Cereda
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:63-71. 2010
    ..These studies thus identify NGEP as a potential target for T cell-mediated immunotherapy of prostate cancer...
  5. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
    ..These results suggest that definitive clinical trials combining antiangiogenic agent combinations with docetaxel are warranted to improve treatment outcomes for patients with metastatic CRPC...
  6. pmc Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:3060-9. 2008
    ..Carcinoembryonic antigen (CEA) and MUC-1 are overexpressed in a substantial proportion of common solid carcinomas. The primary end point of this study was vaccine safety, with immunologic and clinical responses as secondary end points...
  7. pmc Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:663-74. 2010
    ..This hypothesis-generating study provides evidence that patients with more indolent mCRPC (Halabi predicted survival > or =18 months) may best benefit from vaccine therapy...
  8. pmc A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
    William D Figg
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Urol 181:1104-13; discussion 1113. 2009
    ..We determined whether thalidomide can prolong progression-free survival in men with biochemically recurrent prostate cancer treated with limited androgen deprivation therapy...
  9. pmc Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant
    Robert J Lechleider
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 14:5284-91. 2008
    ..We hypothesized that a "metronomic" dose of interleukin 2 (IL-2) as a biological adjuvant would cause less toxicity while maintaining immunologic response...
  10. pmc Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
    Jeanny B Aragon-Ching
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    BJU Int 103:1636-40. 2009
    ..Secondary endpoints included pharmacokinetics, toxicity analysis and overall survival...
  11. pmc A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 1750, USA
    Clin Cancer Res 12:1260-9. 2006
    ..Secondary end points were whether vaccine could be given safely with docetaxel and the clinical outcome of the treatment regimen...
  12. ncbi request reprint Costimulatory molecules as adjuvants for immunotherapy
    James W Hodge
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Front Biosci 11:788-803. 2006
    ..This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines...
  13. ncbi request reprint Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Oncol 13:501-8. 2012
    ..We aimed to assess the safety and tolerability of ipilimumab in combination with a poxviral-based vaccine targeting prostate-specific antigen (PSA) and containing transgenes for T-cell co-stimulatory molecule expression, including CD80...
  14. ncbi request reprint Clinical safety of a viral vector based prostate cancer vaccine strategy
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 178:1515-20. 2007
    ....
  15. ncbi request reprint TRICOM vector based cancer vaccines
    Charlie T Garnett
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute NIH, Bldg 10, Rm 8B09, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 12:351-61. 2006
    ..In this article, preclinical findings and recent clinical applications of TRICOM-based vaccines as a cancer immunotherapy are reviewed...
  16. pmc Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
    Marijo Bilusic
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Immunol Immunother 63:225-34. 2014
    ..Further studies are required to determine the clinical benefit of yeast-CEA vaccination...
  17. pmc A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer
    Mahsa Mohebtash
    Medical Oncology Branch and Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:7164-73. 2011
    ..This study was conducted to obtain preliminary evidence of clinical response in metastatic breast and ovarian cancer patients...
  18. pmc A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver
    James L Gulley
    National Cancer Institute, National Institutes of Health, Center for Cancer Research, Laboratory of Tumor Immunology and Biology, 10 Center Dr, 8B09 MSC 1750, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 11:1409-18. 2011
    ..This pilot study evaluated the tolerability of a vector-based vaccine targeting carcinoembryonic antigen (CEA) in combination with radiation therapy in patients with gastrointestinal malignancies metastatic to the liver...
  19. ncbi request reprint Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 174:539-46. 2005
    ..This trial was designed to analyze toxicity, immunogenicity and time to treatment failure using vaccine, antiandrogen therapy or their sequential use...
  20. ncbi request reprint Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Medical Oncology Clinical Research Unit, Radiation Oncology Branch, and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:3353-62. 2005
    ..One potential solution is the utilization of a well-tolerated systemic therapy (e.g., vaccine) in concert with local therapy...
  21. ncbi request reprint Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone
    Shenhong L Wu
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    BJU Int 99:525-8. 2007
    ....
  22. pmc A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer
    William D Figg
    Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 183:2219-26. 2010
    ....
  23. pmc Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:4526-31. 2008
    ..We now report survival analyses at 6.5 years from the initiation of therapy with a median potential follow-up of 4.4 years...
  24. ncbi request reprint Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
    William L Dahut
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 22:2532-9. 2004
    ..Both docetaxel and thalidomide have demonstrated activity in androgen-independent prostate cancer (AIPC). We compared the efficacy of docetaxel to docetaxel plus thalidomide in patients with AIPC...
  25. ncbi request reprint A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229)
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute National Institutes of Health, Bethesda, MD 20892 1750, USA
    Clin Breast Cancer 7:176-9. 2006
  26. ncbi request reprint Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer
    Marc R Theoret
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Genitourin Cancer 5:347-50. 2007
  27. pmc Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination
    Matteo Vergati
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 60:197-206. 2011
    ..Patients with an OS > HPS were more likely to have decreased Treg function following vaccine. Larger studies to confirm and extend these findings are warranted...
  28. pmc Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents
    Jeanny B Aragon-Ching
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Invest 27:221-6. 2009
    ..Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ...
  29. pmc Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer
    James L Gulley
    Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 180:1432-7; discussion 1437. 2008
    ..To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy...
  30. pmc Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
    Ravi A Madan
    National Cancer Institute, National Institutes of Health, Center for Cancer Research, Laboratory of Tumor Immunology and Biology, Bethesda, MD 20892, USA
    Expert Opin Investig Drugs 18:1001-11. 2009
    ..Additional strategies are in development to further enhance the clinical benefits of Prostvac, and a Phase III trial is being planned in metastatic castration-resistant prostate cancer...
  31. pmc Phase I study of oral lenalidomide in patients with refractory metastatic cancer
    William L Dahut
    PharmD, MBA, Medical Oncology Branch, Building 10 Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Pharmacol 49:650-60. 2009
    ..Grade 3/4 events were predominantly hematologic. Lenalidomide was well tolerated up to a 35-mg/d intermittent dosing schedule at doses higher than previously indicated for hematologic malignancies...
  32. pmc Cancer vaccines: moving beyond current paradigms
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 13:3776-82. 2007
    ..Consequently, evidence is emerging from several studies in which patient cohorts who first receive a cancer vaccine (as contrasted with control cohorts) benefit clinically from subsequent therapies...
  33. ncbi request reprint Therapeutic vaccines for prostate cancer: a review of clinical data
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892 1750, USA
    Curr Opin Investig Drugs 6:592-6. 2005
    ..This review will discuss the rationale for the development of vaccines involving whole tumor cells and dendritic cells, as well as pox viral vectors, and will summarize selected clinical studies that have incorporated these strategies...
  34. ncbi request reprint Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4)
    Junko Yokokawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
    Int J Cancer 121:595-605. 2007
    ..The studies reported here are the first to describe a PAGE4 CTL epitope and its agonist epitope, and thus identify PAGE4 as a potentially useful target for vaccine-mediated therapy of prostate cancer...
  35. ncbi request reprint National Cancer Institute intramural approach to advanced prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Prostate Cancer 1:153-62. 2002
    ....
  36. doi request reprint Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer
    Junko Yokokawa
    Authors Affiliation Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
    Clin Cancer Res 14:1032-40. 2008
    ..In this study, we investigated the number and functionality of CD4+CD25(high)FoxP3+ Tregs in patients with prostate cancer (PCa), and their potential role in inhibiting antitumor immune responses...
  37. ncbi request reprint Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules
    Kwong Y Tsang
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 11:1597-607. 2005
    ..Two antigens expressed noncoordinately on most human carcinomas are carcinoembryonic antigen (CEA) and MUC-1. We report here the construction and characterization of two viral vector vaccines to address these issues...
  38. ncbi request reprint A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive
    Jean Baptiste Lattouf
    Urologic Oncology Branch, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Genitourin Cancer 5:89-92. 2006
  39. doi request reprint A phase II clinical trial of sorafenib in androgen-independent prostate cancer
    William L Dahut
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:209-14. 2008
    ....
  40. ncbi request reprint Immunotherapy for prostate cancer: what's the future?
    Philip M Arlen
    Clinical Research Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, MSC 1750, Bethesda, MD 20892 1750, USA
    Hematol Oncol Clin North Am 20:965-83, xi. 2006
    ..A summary of selected clinical studies incorporating these strategies and new approaches incorporating a combination of immunotherapy with traditional treatments for prostate cancer is presented...
  41. ncbi request reprint Paradigm shifts in cancer vaccine therapy
    Jeffrey Schlom
    Laboratory of Tumor Immunology and Biology, CCR, NCI, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA
    Exp Biol Med (Maywood) 233:522-34. 2008
    ..The unique features of this modality require the consideration of paradigm shifts both in the way cancer vaccine clinical trials are designed and in the way patient benefit is evaluated...
  42. ncbi request reprint A phase II study of perifosine in androgen independent prostate cancer
    Edwin M Posadas
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:1133-7. 2005
    ..The primary objective of this study was to determine the clinical efficacy of this agent in the treatment of androgen-independent prostate cancer (AIPC) using PSA and clinical criteria...
  43. pmc Promising novel immunotherapies and combinations for prostate cancer
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Future Oncol 5:187-96. 2009
    ..This review focuses on the future of promising new vaccines and novel perspectives in the treatment of prostate cancer...
  44. ncbi request reprint Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Am J Ther 11:238-41. 2004
    ..When his PSA level rose on nilutamide, he commenced treatment with the vaccine therapy. He has continued to have a PSA response with the vaccine treatments with no radiographic evidence disease for >20 months...
  45. pmc Enhancing efficacy of therapeutic vaccinations by combination with other modalities
    James L Gulley
    Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Vaccine 25:B89-96. 2007
    ..Large randomized studies are currently underway to further investigate these findings...
  46. ncbi request reprint Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer
    Philip M Arlen
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Expert Rev Vaccines 2:483-93. 2003
    ..Newer approaches incorporating costimulatory molecules that enhance Tcell activation are also being investigated...
  47. ncbi request reprint Pox viral vaccine approaches
    Philip M Arlen
    Laboratory of Tumor Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 32:549-55. 2005
    ....
  48. pmc Therapeutic prostate cancer vaccines: a review of the latest developments
    Mahsa Mohebtash
    National Cancer Institute, Center for Cancer Research, Laboratory of Tumor Immunology and Biology, 10 Center Drive, Building 10, Room 8B09, MSC 1750, Bethesda, MD 20892 1750, USA
    Curr Opin Investig Drugs 9:1296-301. 2008
    ..This review discusses different types of cancer vaccines, with a focus on prostate cancer vaccines because of the high prevalence of prostate cancer and the wide variety of approaches used in prostate cancer immunotherapy...
  49. ncbi request reprint PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
    Ravi A Madan
    Clinical Immunotherapy Group, National Cancer Institute NCI, Laboratory of Tumor Immunology and Biology, National Institutes of Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 7:543-54. 2007
    ..Studies to date hold promise for the use of PANVAC as a means to stimulate the immune system against malignancies and to provide clinical benefit...
  50. ncbi request reprint Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases
    James L Gulley
    Medical Oncology Branch, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Genitourin Cancer 5:403-5. 2007
    ....
  51. doi request reprint Recent advances revolutionize treatment of metastatic prostate cancer
    Ravi A Madan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA
    Future Oncol 9:1133-44. 2013
    ....
  52. ncbi request reprint Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors
    William L Dahut
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 5:22-7. 2006
    ..To determine the maximum-tolerated dose (MTD) and toxicity profile of the novel anticancer agent, 2-methoxyestradiol (2ME2) administered orally, in patients with solid tumors...
  53. ncbi request reprint A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors
    Christoph M Ahlers
    Medical Oncology Branch, Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health 20892, USA
    Clin Colorectal Cancer 6:72-5. 2006
  54. pmc Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time
    Philip M Arlen
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 179:2181-5; discussion 2185-6. 2008
    ..It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting...
  55. pmc Cancer vaccines: current directions and perspectives in prostate cancer
    Mahsa Mohebtash
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Curr Opin Mol Ther 11:31-6. 2009
    ..This review focuses on promising new strategies for combining vaccines with other therapeutic approaches, as well as novel perspectives in the treatment of prostate cancer...
  56. ncbi request reprint PSA-based vaccines for the treatment of prostate cancer
    Ravi A Madan
    National Cancer Institute, Medical Oncology Branch, National Institutes of Health, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA
    Expert Rev Vaccines 5:199-209. 2006
    ..New approaches incorporating a combination of a vaccine with traditional treatments for prostate cancer are also being investigated...
  57. pmc Current perspectives in prostate cancer vaccines
    Philip M Arlen
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1750, USA
    Anticancer Agents Med Chem 9:1052-7. 2009
    ..This review focuses on promising new vaccines and novel perspectives in the treatment of prostate cancer...
  58. ncbi request reprint A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1
    Philip M Arlen
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol Methods 279:183-92. 2003
    ..Increases in CEA peptide precursors were noted in all five patients using the B7-1-infected APC. In conclusion, we have demonstrated the ability to enhance the sensitivity of the ELISPOT assay through infection of C1RA2 with rF-B7-1...
  59. ncbi request reprint Therapeutic vaccines for prostate cancer
    Christopher P Tarassoff
    F A C P, National Cancer Institute, Clinical Immunotherapy Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, 10 Center Drive, MSC 1750, Building 10, Room 5B52, Bethesda, Maryland 20892, USA
    Oncologist 11:451-62. 2006
    ..This review highlights recent advances and clinical trials in immunotherapy for prostate cancer, along with current thoughts on immunologic and clinical monitoring of these trials...
  60. ncbi request reprint Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy
    Nushin F Todd
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Ther 12:172-4. 2005
    ..Further investigation of the potential role of nilutamide therapy as second-line antiandrogen therapy is warranted as monotherapy and/or in combination with other promising novel approaches including PSA-based vaccines...
  61. ncbi request reprint A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer
    Tanyifor M Tohnya
    Clinical Pharmacology Research Core, National Institutes of Health, Bethesda, MD, USA
    Clin Prostate Cancer 2:241-3. 2004
  62. ncbi request reprint Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
    James Gulley
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Prostate 53:109-17. 2002
    ..A Phase I trial of recombinant vaccinia prostate specific antigen (rV-PSA) in patients with advanced metastatic prostate cancer was conducted. This report describes 42 patients who were treated with up to three monthly vaccinations...
  63. doi request reprint Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
    Philip M Arlen
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Expert Rev Vaccines 11:287-302. 2012
    ....
  64. ncbi request reprint Abiraterone. Cougar Biotechnology
    Ravi A Madan
    National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    IDrugs 9:49-55. 2006
    ..Phase I clinical trials of abiraterone have been conducted and the design of phase I/II clinical trials is being finalized...
  65. ncbi request reprint Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
    John L Marshall
    Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 23:720-31. 2005
    ..We describe here the first trial in humans of the CEA-TRICOM vaccines (also including an enhancer agonist epitope within the CEA gene)...